Lomitapide is currently in clinical development for the treatment of paediatric patients with homozygous familial hypercholesteraemia (HoFH) receiving stable lipid-lowering therapy. HoFH is a more severe form of familial hypercholesterolaemia, a condition passed down through families, which raises blood low density lipoprotein (LDL) cholesterol to very high levels. Low density lipoprotein cholesterol (LDL-C) is often referred to as ‘bad cholesterol’. Attempts to lower LDL-C levels often require multiple lipid-lowering drugs and LDL apheresis. Despite these therapies, most patients with HoFH do not reach guideline-recommended LDL-C levels.
Lomitapide for treating homozygous familial hypercholesterolaemia in children aged 5 to 17 years
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Lomitapide is currently in clinical development for the treatment of paediatric patients with homozygous familial hypercholesteraemia (HoFH) receiving stable lipid-lowering therapy.
Interventions:
Lomitapide
Indications:
Homozygous familial hypercholesterolaemia
Therapeutic Areas:
Endocrine Nutritional and Metabolic Disorders
Year:
2024